Redeye comments on QleanAir’s reported Q4’21 figures, where organic sales growth exceeded our expect...
Redeye comments on the announced rights issue in Alzecure.
Redeye comment on Remedy’s full-year report. Remedy posted an EBIT result in line with our estimated...
Q4 quite in line with expectations Etteplan reported Q4 results quite in line with expectations.
Tough quarter behind The company’s net sales decreased by 4% y/y to EUR 168.
Sparekassen Sjælland-Fyn reported profit before loan losses of DKK 105m for Q4 2021, which was a who...
Redeye is encouraged to learn that the ongoing SAN711 phase I study (n=80), now in the MAD (”multipl...
Den 10 februari 2022 publicerade Aptahem sin delårsrapport för fjärde kvartalet 2021.
Redeye endorses aXichem signing a business collaboration agreement with GCV Life to commercialize aX...
Etteplan's net sales in Q4 amounted to EUR 85.3m (EUR 82.
Sparekassen Sjælland-Fyn reported Q4 PBLL of DKK 105m, DKK 18m (21%) above our estimate.
Starkt resultat ITAB rapporterade en EBIT på 224 mkr, vilket var i linje med vår prognos (216 mkr).
Ascelia continues to advance the pivotal Mangoral (Orviglance) study, which is also supported by rec...
Redeye sees a solid Q4 from Bredband2, with sales and EBIT coming in as we expected.
Redeye is encouraged by today’s interim data from Vicore’s open-label phase II study in IPF, which a...
Redeye retains its positive view on Transtema following the Q4 report despite a somewhat softer adju...
Pihlajalinna reports Q4 results on Fri, Feb 18. We make small positive revisions to our Q4 estimates...
We expect a solid Q4 report for Ferronordic on 18 February, with sales up 37% y/y and adjusted EBIT ...
Verkkokauppa.com’s Q4 topline fell short of our expectations.
Redeye takes a more positive stance towards Proact following the Q4 report, despite showing declinin...
